Hematology

Of 724 patients treated at the center, the cumulative incidence of secondary hematologic malignancy at 3 years posttreatment was 6.5%.

Review top news and interview highlights from the week ending July 19, 2024.

The associate professor of medicine at University of Colorado discussed data presented at ASCO 2024.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA announced its START Pilot Program in October 2023 with a similar goal.

Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment

In light of the CTN clearance, Interius expects to initiate plans for a phase 1 clinical trial (INVISE) for INT2104 within the final quarter of 2024.

Review top news and interview highlights from the week ending July 12, 2024.

GT Biopharma anticipates initiating the phase 1 clinical trial in the second half of 2024.

Tr1X reported that the first patient has cleared the trial’s safety period successfully, having experienced no serious adverse events.

The open-label, single-arm, multisite NEXICART-2 study will aim to enroll around 40 participants in total.

The associate professor of medicine at University of Colorado discussed how the field has shifted to support the growing use of CAR Ts and progress to come.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending July 5, 2024.

The associate professor of medicine at University of Colorado discussed a post hoc analysis study on subgroup analyses of liso-cel response.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Patients in FUMANBA-2 received eque-cel after being ineligible for ASCT after 4 cycles of induction therapy.

The professor in residence for pediatrics at the Sickle Cell Center of Excellence at the University of California discussed gene therapy’s ongoing transformation of the treatment landscape.

Eight patients receiving either TSC-100 or TSC-101 have been disease-free for a median of 10 months of follow-up.

Review top news and interview highlights from the week ending June 28, 2024.

The associate professor of medicine at University of Colorado discussed data in the primary relapsed LBCL setting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending June 21, 2024.

Data from up to 5 and 6 years of follow-up were presented at the 2024 EHA Congress.